Revolution Medicines, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for patients with RAS-addicted cancers, which represent approximately 30% of human cancers; its research and development pipeline centers on proprietary RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, including the pan-RAS inhibitor daraxonrasib (RMC-6236), the RAS(ON) G12C-selective inhibitor elironrasib (RMC-6291), and the RAS(ON) G12D-selective inhibitor zoldonrasib (RMC-9805). These inhibitors target previously undruggable frontier targets in the RAS pathway and mTOR signaling through tri-complex mechanisms to enhance drug-target engagement and overcome resistance. The company operates primarily in the United States with global clinical development activities and serves patients and healthcare providers in oncology. Founded in 2014 and headquartered in Redwood City, California, Revolution Medicines leverages its RAS(ON) drug discovery platform to advance late-stage programs. In June 2025, the company entered a transformative $2 billion funding arrangement with Royalty Pharma, comprising up to $1.25 billion in synthetic royalty financing (with $250 million upfront) on daraxonrasib and up to $750 million in senior secured debt to support global development, Phase 3 trials in pancreatic cancer and non-small cell lung cancer, commercialization, and pipeline expansion; this partnership enables Revolution Medicines to retain full control over its programs while advancing multiple Phase 3 trial launches. Recent updates include progress on daraxonrasib's Phase 3 readiness and a technology collaboration with Iambic announced in November 2025 to further enhance its RAS inhibitor portfolio.
Bessemer Group Inc. Sells 69,600 Shares of Revolution Medicines, Inc. $RVMD
This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It
5 Stock Setups Where Wall Street Sees the Most Upside Right Now
Better Growth Buy: Axsome vs Revolution Medicines
European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
After Apogee, 3 More Biotech Buyout Targets Wall Street Can't Stop Watching
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
Revolution Medicines: Strong Data, Big Market (Rating Upgrade)
Can Revolution Medicines Be a Game-Changer Stock?
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.
Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript